Evidence map›Paper›PMID 27180823›Full record

ArticleEpidemiology and infection2016

Higher organism load associated with failure of azithromycin to treat rectal chlamydia.

F Y S Kong, S N Tabrizi, C K Fairley, S Phillips, G Fehler, M Law, L A Vodstrcil, M Chen, C S Bradshaw, J S Hocking

Abstract read
In one paragraph

Article in Epidemiology and infection, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Observational
  12. Review
  13. Review
  14. A snapshot of Chlamydia trachomatis genetic diversity using multilocus sequence type analysis in an Australian metropolitan setting.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2017
    Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

F Y S KongMelbourne School of Population and Global Health,University of Melbourne,Victoria,Australia.
S N TabriziDepartment of Obstetrics and Gynaecology,University of Melbourne,Victoria,Australia.
C K FairleyMelbourne Sexual Health Centre,Alfred Health and Central Clinical School,Monash University,Victoria,Australia.
S PhillipsRoyal Women's Hospital and Murdoch Children's Research Institute.
G FehlerMelbourne Sexual Health Centre,Alfred Health and Central Clinical School,Monash University,Victoria,Australia.
M LawKirby Institute,University of New South Wales,Sydney,Australia.
L A VodstrcilMelbourne School of Population and Global Health,University of Melbourne,Victoria,Australia.
M ChenMelbourne School of Population and Global Health,University of Melbourne,Victoria,Australia.
C S BradshawMelbourne School of Population and Global Health,University of Melbourne,Victoria,Australia.
J S HockingMelbourne School of Population and Global Health,University of Melbourne,Victoria,Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Repeat rectal chlamydia infection is common in men who have sex with men (MSM) following treatment with 1 g azithromycin. This study describes the association between organism load and repeat rectal chlamydia infection, genovar distribution, and efficacy of azithromycin in asymptomatic MSM. Stored rectal chlamydia-positive samples from MSM were analysed for organism load and genotyped to assist differentiation between reinfection and treatment failure. Included men had follow-up tests within 100 days of index infection. Lymphogranuloma venereum and proctitis diagnosed symptomatically were excluded. Factors associated with repeat infection, treatment failure and reinfection were investigated. In total, 227 MSM were included - 64 with repeat infections [28·2%, 95% confidence interval (CI) 22·4-34·5]. Repeat positivity was associated with increased pre-treatment organism load [odds ratio (OR) 1·7, 95% CI 1·4-2·2]. Of 64 repeat infections, 29 (12·8%, 95% CI 8·7-17·8) were treatment failures and 35 (15·4%, 95% CI 11·0-20·8) were reinfections, 11 (17·2%, 95% CI 8·9-28·7) of which were definite reinfections. Treatment failure and reinfection were both associated with increased load (OR 2·0, 95% CI 1·4-2·7 and 1·6, 95% CI 1·2-2·2, respectively). The most prevalent genovars were G, D and J. Treatment efficacy for 1 g azithromycin was 83·6% (95% CI 77·2-88·8). Repeat positivity was associated with high pre-treatment organism load. Randomized controlled trials are urgently needed to evaluate azithromycin's efficacy and whether extended doses can overcome rectal infections with high organism load.

Indexed as

Bacterial LoadAdolescentAdultAgedAnti-Bacterial AgentsAzithromycinChlamydia InfectionsChlamydia trachomatisHumansMaleMiddle AgedRectal DiseasesRectumRetrospective StudiesRiskSexual and Gender MinoritiesAnti-Bacterial AgentsAzithromycinChlamydia trachomatisgenovarorganism loadrectalrepeat infection

Identifiers

PMID27180823
PMCPMC9150464

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.